Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.

@article{Montemurro2003SafetyAA,
  title={Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.},
  author={Filippo Montemurro and Gabriella Choa and Roberto Faggiuolo and Elisa Sperti and Antonio Capaldi and Michela Donadio and Monica Minischetti and Attilio Salomone and Guido Vietti-Ramus and Oscar Alabiso and Massimo Aglietta},
  journal={American journal of clinical oncology},
  year={2003},
  volume={26 1},
  pages={95-7}
}
We conducted a pilot phase II trial of trastuzumab administered concurrently with docetaxel in women with HER2-overexpressing advanced breast cancer. Twenty-five women with HER2-positive (3+ by immunohistochemistry = 16, 2+ = 9) metastatic breast cancer received docetaxel (75 mg/m every 3 weeks for 6 cycles) and trastuzumab (4 mg/kg loading dose, 2 mg/kg weekly thereafter). Twenty-three patients (92%) had visceral metastatic involvement. Twenty-three patients had received prior chemotherapy as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…